The Event Brought the Austin Community Together for a Night of Fun with a Purpose Featuring Gourmet Food, Cocktails, Casino Games and More NEWPORT BEACH, Calif., April 6, 2022 – […]
CureDuchenne is happy to share the news that REGENXBIO will be launching a novel gene therapy trial in Duchenne during the first half of 2022. RGX-202 aims to deliver a […]
Investment to Expand First-in-Class, Nucleic Acid Therapeutics Towards Targeting Muscle Diseases Newport Beach, Calif. (December 22, 2021) – CureDuchenne Ventures, a subsidiary of CureDuchenne, a leading global nonprofit focused on […]
Brigham and Women’s Hospital Becomes Only US Birth Hospital with a Program Offering Parents a Choice to Have Supplemental Newborn Screening for Duchenne Muscular Dystrophy **UPDATE** In part as a […]
CureDuchenne Link™ is a Centralized Hub with Data and Biosamples for Researchers Around the World Newport Beach, CA (June 18, 2021) – CureDuchenne, a leading global nonprofit focused on finding […]
NEWPORT BEACH, Calif., Mar. 18, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about […]
NEWPORT BEACH, Calif., Jan. 14, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a new initiative centered on the COVID-19 vaccine rollout […]
Newport Beach, CA (January 08, 2021) – (BUSINESS WIRE)–CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) […]
Newport Beach, CA, December 21, 2020 – CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver […]
